These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 36369073)

  • 1. Impact of a statewide community pharmacy approach to opioid harm reduction.
    Sexton SM; Marciniak MW; Gatton O; Shelton P
    J Am Pharm Assoc (2003); 2023; 63(1):389-395.e1. PubMed ID: 36369073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Examining the effects of COVID-19 on pharmacy dispensing of naloxone and syringes sales across Massachusetts and New Hampshire.
    Bolivar D; Hartung D; Silcox J; Bratberg J; Boggis J; Rabin M; Green TC
    J Am Pharm Assoc (2003); 2023; 63(1):330-335.e1. PubMed ID: 36369076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "Like it was just everyday business": A qualitative study of pharmacy-based naloxone and syringe customer experience.
    Gray M; Shin SS; Silcox J; Flores D; Bolivar D; Irwin AN; Floyd AS; Bratberg J; Boggis JS; Hartung DM; Green TC
    J Am Pharm Assoc (2003); 2023; 63(3):838-846. PubMed ID: 36872182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study protocol for the Respond to Prevent Study: a multi-state randomized controlled trial to improve provision of naloxone, buprenorphine and nonprescription syringes in community pharmacies.
    Green TC; Bratberg J; Irwin AN; Boggis J; Gray M; Leichtling G; Bolivar D; Floyd A; Al-Jammali Z; Arnold J; Hansen R; Hartung D
    Subst Abus; 2022; 43(1):901-905. PubMed ID: 35213293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonprescription naloxone and syringe sales in the midst of opioid overdose and hepatitis C virus epidemics: Massachusetts, 2015.
    Stopka TJ; Donahue A; Hutcheson M; Green TC
    J Am Pharm Assoc (2003); 2017; 57(2S):S34-S44. PubMed ID: 28189540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implementation of a statewide program within community pharmacies to prevent opioid misuse and accidental overdose.
    Skoy E; Eukel H; Werremeyer A; Strand M; Frenzel O; Steig J
    J Am Pharm Assoc (2003); 2020; 60(1):117-121. PubMed ID: 31677933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of policy changes on the provision of naloxone by pharmacies in Ontario, Canada: a population-based time-series analysis.
    Antoniou T; Martins D; Campbell T; Tadrous M; Munro C; Leece P; Mamdani M; Juurlink DN; Gomes T
    Addiction; 2021 Jun; 116(6):1514-1520. PubMed ID: 33207025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evaluation of mandatory alerts on long-acting opioid prescriptions and the use of a community pharmacy naloxone protocol.
    Coffman R; Johnson A; Frede S; Pleiman M; Johnson K
    J Am Pharm Assoc (2003); 2022; 62(4S):S35-S40.e1. PubMed ID: 34930681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacists' nonprescription syringe dispensing perceptions and behaviors: A three-state descriptive analysis.
    Hagemeier NE; Dowling-McClay K; Baladezaei M; Curtis SJ; Spence M
    Drug Alcohol Depend; 2021 Apr; 221():108597. PubMed ID: 33631542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of a pharmacist-driven intervention on the outpatient dispensing of naloxone.
    Griffin S; Wishart B; Bricker K; Luebchow A
    J Am Pharm Assoc (2003); 2019; 59(4S):S161-S166. PubMed ID: 31326040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A standardized team-based approach for identifying naloxone-eligible patients in a grocery store pharmacy.
    Sexton SM; Armstrong A; Gatton O; Rhodes LA; Marciniak MW
    J Am Pharm Assoc (2003); 2019; 59(4S):S95-S100. PubMed ID: 31231001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementation of academic detailing for pharmacists on opioid use disorder and harm reduction.
    DiPaula BA; Cooke CE; Boyle CJ; Love RC
    J Am Pharm Assoc (2003); 2022; 62(1):241-246. PubMed ID: 34690080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Public Health and Pharmacy Partnerships in Opioid Harm Reduction: Responding to Community Needs.
    Medina S; Tomaszewski R; Chhen S; Hanson A; Mueller A; Palombi LC
    Prog Community Health Partnersh; 2021; 15(1):37-46. PubMed ID: 33775959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacy on-site overdose protocols and prevention of overdose.
    Green TC; Soipe A; Baloy B; Burstein D; Xuan Z; Tapper A; Walley AY; Case P; Bratberg J; Baird J
    Subst Abus; 2022; 43(1):64-68. PubMed ID: 32186478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Geographic variation in the provision of naloxone by pharmacies in Ontario, Canada: A population-based small area variation analysis.
    Antoniou T; McCormack D; Campbell T; Sutradhar R; Tadrous M; Lum-Wilson N; Leece P; Munro C; Gomes T
    Drug Alcohol Depend; 2020 Nov; 216():108238. PubMed ID: 32891910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying barriers to dispensing naloxone: A survey of community pharmacists in North Carolina.
    Rudolph SE; Branham AR; Rhodes LA; Hayes HH; Moose JS; Marciniak MW
    J Am Pharm Assoc (2003); 2018; 58(4S):S55-S58.e3. PubMed ID: 30006187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparing pharmacists to increase naloxone dispensing within community pharmacies under the Pennsylvania standing order.
    Santa HM; Amirova SG; Ventricelli DJ; Downs GE; Nowalk AA; Pringle JL; Aruru M
    Am J Health Syst Pharm; 2021 Feb; 78(4):327-335. PubMed ID: 33336254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Naloxone Coprescription Laws With Naloxone Prescription Dispensing in the United States.
    Sohn M; Talbert JC; Huang Z; Lofwall MR; Freeman PR
    JAMA Netw Open; 2019 Jun; 2(6):e196215. PubMed ID: 31225895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility and acceptability of a proposed pharmacy-based harm reduction intervention to reduce opioid overdose, HIV and hepatitis C.
    Meyerson BE; Agley JD; Jayawardene W; Eldridge LA; Arora P; Smith C; Vadiei N; Kennedy A; Moehling T;
    Res Social Adm Pharm; 2020 May; 16(5):699-709. PubMed ID: 31611071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilot implementation of the PharmNet naloxone program in an independent pharmacy.
    Eldridge LA; Meyerson BE; Agley J
    J Am Pharm Assoc (2003); 2023; 63(1):374-382.e12. PubMed ID: 36209035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.